Objective: The etiology and pathogenesis of moyamoya disease remain unclear. Furthermore, the definitive diagnostic protein-biomarkers for moyamoya disease are still unknown. The present study analyzed serum proteomes from normal controls and moyamoya patients to identify novel serological biomarkers for diagnosing moyamoya disease.

Methods: We compared the two-dimensional electrophoresis patterns of sera from moyamoya disease patients and normal controls and identified the differentially-expressed spots by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry and electrospray ionization quadruple time-of-flight mass spectrometry.

Results: We found and analyzed 22 differently-expressed proteomes. Two proteins were up-regulated. Twenty proteins were down-regulated. Complement C1 inhibitor protein and apolipoprotein C-III showed predominantly changed expressions (complement C1 inhibitor protein averaged a 7.23-fold expression in moyamoya patients as compared to controls, while apolipoprotein C-III averaged a 0.066-fold expression).

Conclusion: Although our study had a small sample size, our proteomic data provide serologic clue proteins for understanding moyamoya disease.

KEY WORDS: Moyamoya disease · Proteome.

INTRODUCTION

Moyamoya disease is defined by progressive stenosis and occlusion of the terminal portions of the bilateral internal carotid arteries. Many studies have investigated the pathophysiology of moyamoya disease. However, the cause and pathogenesis of moyamoya disease are still unknown.

Previous studies have suggested a correlation between certain genetic factors and the pathogenesis of this disease. Researchers performing CSF studies of moyamoya patients have commented on correlations between the presence of the disease and basic fibroblast growth factor (b-FGF), intercellular adhesion molecule Type-1 (ICAM-1), vascular cell adhesion molecule Type-1 (VCAM-1), and E-selectin level.

Histopathologic studies have shown that the presence of mural thrombi is the most probable culprit in the generation of intimal lesions, and other studies have suggested a correlation with inflammatory stimuli. There have been no serologic studies of moyamoya disease, however. In our study, we analyzed the serum proteomes of both adult patients with moyamoya disease and normal controls, attempting to find the key proteins associated with moyamoya disease.

MATERIALS AND METHODS

Sampling of sera

We collected venous blood from 6 moyamoya-disease patients and 6 normal controls. We recruited moyamoya patients with different clinical symptom and different Suzuki grade to avoid over- or down-regulated proteins are limited to a specific stage of moyamoya disease. Six normal controls had no vascular abnormalities, confirming the diagnoses via transfemoral cerebral angiography. To minimize individual variations, we matched the genders and ages of the moyamoya patients with the controls. Table 1, 2 summarize the profiles of the moyamoya patients and the controls.

Next, we separated out the sera and kept them frozen at...
-80˚C until use. We centrifuged the thawed samples at 4,500 rpm for 10 minutes to remove the fibrinogen and then filtered them (0.45 µm pore size, Millipore, Bedford, MA, USA).

The Ethics Committee of Chonbuk National University Medical School approved this study. The participants were fully informed, and all provided their written consent.

**Two-dimensional electrophoresis**

To desalt the samples, we used dialysis tubing (12k-Da molecular cutoff; Sigma, St. Louis, MO, USA). After desalting, each sample was mixed with a solution containing SDS (10% w/v) and DTT (2.3% w/v) and then heated to 95˚C.

For each sample, 300 µg serum protein in rehydration solution [8 mol/L urea, 2% CHAPS, 0.5% immobilized pH gradient (IPG) buffer, 1% DTT, and a trace of bromophenol blue] was loaded onto an Immobiline Dry Strip (PI 3-10, 24 cm) (Amersham Biosciences, Uppsala, Sweden) for 5 minutes.

We performed the first-dimension isoelectric focusing at 66,000 V/hr and 20˚C, using an IPGPhor IEF system (Amersham Biosciences). Next, we equilibrated the gels 30 minutes each in equilibration buffer I [50 mmol/L Tris-Cl (Ph 8.8), 6 mol/L urea, 30% glycerol, 2% SDS, and 0.25% IAA].

We ran the second-dimension gel electrophoresis according to the Ettan DALT II system operating manual (Amersham Biosciences), which requires placing the IPG strips on the surface of the second-dimension gel (a 24 cm, 12.5% SDS-polycrylamide slab gel) and then sealing the IPG strips with 0.5% agarose in SDS electrophoresis buffer (25 mmol/L Tris base, 192 mmol/L glycline, and 0.1% SDS). These gels were run overnight at 110 volts.

**Silver staining**

To silver stain the gels, we employed a modified silver staining protocol, using a Silver Stain PlusOne kit (Amersham Biosciences) and omitting the use of glutaraldehyde in the sensitization step and formaldehyde in the silver impregnation step. After electrophoresis, the gels were fixed with 40% methanol and 10% acetic acid for 30 minutes. The gels were sensitized by incubating them in sensitizing solution (0.2% sodium thiosulphate, 30% methanol, and sodium acetate, 68 g/L). We then rinsed the gels with 3 changes of distilled water at 5 minutes/rinse. After running, the gels were incubated in 0.25% silver nitrate for 20 minutes. Next, we discarded the silver nitrate, rinsed the gels twice with distilled water, 1 minute/rinse, and then developed them, with intensive shaking, in 2.5% sodium carbonate containing 0.15% formaldehyde. After we achieved the desired staining intensity, we terminated the gels’ development using 1.46% ethylenediaminetetraacetic acid (EDTA).

**Image analysis**

We scanned the silver-stained two-dimensional electrophoresis (2-DE) gels, using LabScan software on an image scanner (Amersham Biosciences) and digitized and analyzed the information using an Image Master 2D (Amersham Biosciences), carrying out spot standardization on all the matched spots. Then we normalized each spot volume (intensity) as a percentage of the total spot volume, using only the spots that were present on all the gels.

**Destaining**

To destain the silver-stained proteins, we used chemical reducers as described Scheler et al.21, as follows. We prepared two stock solutions, 30 mM potassium ferricyanide and 100 mM sodium thiosulfate, dissolved in water. We mixed each working solution by mixing a 1 : 1 ratio prior to use. After we excised the gel sections containing the protein spots of interest, we added 30-50 mL working solution to cover these gels, vortexing them occasionally. We monitored stain intensity until the brownish color disappeared, then rinsed each gel with water a few times, to halt the reaction. Next, we covered each gel with 200 mM ammonium bicarbonate for 20 minutes and then discarded the solution. Subsequently, we cut each gel into small pieces, washed these with water, and dehydrated them repeatedly with fresh acetonitrile until the

---

**Table 1.** Profiles of patients with moyamoya disease

| no. | Age (yrs) | Sex | Clinical manifestation | Suzuki grade |
|-----|-----------|-----|------------------------|--------------|
| 1   | 35        | M   | IVH                    | III          |
| 2   | 50        | F   | IVH                    | IV           |
| 3   | 42        | F   | No hemorrhage or infarction | V          |
| 4   | 64        | F   | ICH                    | II           |
| 5   | 63        | M   | Infarction             | IV           |
| 6   | 53        | M   | Infarction             | III          |

F : female, IVH : intraventricular hemorrhage, ICH : intracerebral hemorrhage, M : male, yrs : years

**Table 2.** Profiles of normal controls

| no. | Age (yrs) | Sex | Clinical manifestation | Vascular abnormality |
|-----|-----------|-----|------------------------|----------------------|
| 1   | 40        | F   | Headache               | Absent               |
| 2   | 48        | F   | Headache               | Absent               |
| 3   | 50        | F   | Headache               | Absent               |
| 4   | 38        | M   | Headache               | Absent               |
| 5   | 43        | M   | Headache               | Absent               |
| 6   | 51        | M   | Headache               | Absent               |

F : female, M : male, yrs : years
pieces became opaque white in color. Finally, the gel pieces were dried in a vacuum centrifuge for 30 minutes.

**Trypsin digestion of proteins in gel**

The enzymatic digestion was performed as described by Hellman and Shevchenko, as follows. The samples incubated overnight, at 37˚C, in 5-10 ng/µL trypsin and 50 mM ammonium bicarbonate. Following this enzymatic digestion, we thrice extracted the resultant peptides with 10-20 µL of 5% trifluoroacetic acid in 50% acetonitrile and dried them 30 minutes in a vacuum centrifuge.

**Identification of proteins**

We analyzed the dried samples using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer [MALDI-TOF MS (Voyager-DE PRO)], for the peptide mass fingerprinting, and via electrospray ionization quadruple time-of-flight (ESI-Q-TOF) mass spectrometry analysis, for the peptide sequencing. The database searches employed MS-fit, which is accessible on the World Wide Web at http://kr.expasy.org and http://www.ncbi.nlm.nih.gov.

**RESULTS**

After routine silver staining procedures, we observed 2000 to 3000 protein spots of about 150 µg. We found 22 significantly different spots, 2 up-regulated and 20 down-regulated (Table 3). After these proteins digested overnight in trypsin, the MALDI-TOF MS and ESI Q-TOF MS analyses identified the up-regulated spots as Ig heavy chain V-III region (spot 556, change of ratio in moyamoya : 2.275 ± 0.44092) and complement C1 inhibitor protein (spot 1987, 7.23 ± 0.10141) (Fig. 1) and the down-regulated spots as apolipoprotein C-III (spot 19, 0.066 ± 0.05231), a covalent dimer of transthyretin (spot 73, 0.642 ± 0.02332), a retinol-binding protein (spot 115, 0.6 ± 0.04899), a proapolipoprotein (spot 304, 0.516 ± 0.14801), PRO 2675 (spots 580, 0.216 ± 0.06329; spot 656, 0.468 ± 0.07081; spot 2369, 0.742 ± 0.04454), PRO 2044 (spot 587, 0.33 ± 0.06189), apolipoprotein E precursor (spot 606, 0.248 ± 0.06909), the X-ray crystal structure of C3d (spot 698, 0.082 ± 0.05553), S100 calcium binding protein A14 (spot 699, 0.116 ± 0.03385), ALB protein (spot 948, 0.592 ± 0.10131), a hy-

### Table 3. The proteins significantly changed in sera of moyamoya patients

| Spot no. | Protein name | Accession number | Rank | pI/Mw (in database) | Moyamoya changes in ratio |
|----------|--------------|------------------|------|---------------------|---------------------------|
| 12       | Non-identification | -                | -    | -                   | 0.54 ± 0.09767            |
| 19       | Apolipoprotein CIII | 224917           | 1    | 4-7/8-75            | 0.066 ± 0.05231           |
| 29       | Non-identification | -                | -    | -                   | 0.332 ± 0.17682           |
| 73       | Chain A, A Covalent Dimer Of Transthyretin that Affects The Amyloid Pathway | 55669575 | 1    | 5.3/12.83           | 0.642 ± 0.02332           |
| 92       | Non-identification | -                | -    | -                   | 0.458 ± 0.1299            |
| 115      | Chain, Retinol Binding Protein | 230284 | 1    | 5.3/21.28           | 0.6 ± 0.04899             |
| 304      | Proapolipoprotein | 178775           | 1    | 5.4/28.94           | 0.516 ± 0.14801           |
| 383      | Non-identification | -                | -    | -                   | 0.608 ± 0.1222            |
| 556      | Ig heavy chain V-III region (ART) - human (fragments) | 106482 | 1    | 5.2/23.92           | 2.275 ± 0.44092           |
| 580      | PRO2675, Serum albumin | 7770217 | 1    | 6.1/33.47           | 0.216 ± 0.06329           |
| 587      | Pro2044, Serum albumin | 6650826 | 1    | 7.0/30.09           | 0.33 ± 0.06189            |
| 606      | Apolipoprotein E precursor | 4557325 | 1    | 5.73/31.924         | 0.248 ± 0.06909           |
| 656      | PRO2675, Serum albumin | 7770217 | 1    | 6.02/37.256         | 0.468 ± 0.07081           |
| 670      | Non-identification | -                | -    | 5.20/34.112         | 0.254 ± 0.11237           |
| 698      | Chain, X-Ray Crystal Structure Of C3d : A C3 Fragment And Ligand For Complement Receptor 2 | 3745750 | 1    | 4.97/38.539         | 0.082 ± 0.05553           |
| 699      | S100 calcium binding protein A14 | 10190712 | 3    | 4.95/37.000         | 0.116 ± 0.03385           |
| 948      | ALB protein | 27692693 | 1    | 6.28/49.863         | 0.592 ± 0.10131           |
| 1003     | Non-identification | -                | -    | 7.10/67.849         | 0 ± 0                     |
| 1987     | Complement C1 inhibitor protein (C1 Inh) (C1Inh) (C1 esterase inhibitor) (C1-inhibiting factor) | 124096 | 1    | 3.47/99.385         | 7.23 ± 0.10141            |
| 2100     | Hypothetical protein | 51476396 | 1    | 6.31/240.272        | 0.314 ± 0.09136           |
| 2354     | Non-identification | -                | -    | 9.97/10.000         | 0.04667 ± 0.04667         |
| 2369     | PRO2675, Serum albumin | 7770217 | 1    | 5.91/37.452         | 0.742 ± 0.04454           |

Mw : molecular weight
porthetical protein (spot 2100, 0.314 ± 0.09136), and some unidentified proteins (spot 12, 0.54 ± 0.09767; spot 29, 0.332 ± 0.17682; spot 92, 0.458 ± 0.1299; spot 383, 0.608 ± 0.1222; spot 670, 0.254 ± 0.11237; spot 1003, 0 ± 0, and spot 2354, 0.04667 ± 0.04667) (Fig. 2).

**DISCUSSION**

Various studies have attempted to discover the pathophysiology of moyamoya disease. However, the cause and pathogenesis of moyamoya disease are still unknown.

Several previous reports have implicated genetic factors in moyamoya's pathogenesis. Researchers have proposed chromosomes 3, 6, 8, 12, and 17 as possible locations of the responsible gene. Ikeda and Yoshimoto reported

---

**Fig. 1.** Up-regulated spots that were significantly and consistently changed in human sera of moyamoya patients compared to normal controls. In each pair of two-dimensional electrophoresis (2-DE) gels from a normal control and a moyamoya patient, the density of a spot in moyamoya gel was normalized to the density of the corresponding spot in the control gel. (characteristics of each spot is shown in Table 3).

**Fig. 2.** Down-regulated spots that were significantly and consistently changed in human sera of moyamoya patients compared to normal controls. In each pair of two-dimensional electrophoresis (2-DE) gels from a normal control and a moyamoya patient, the density of a spot in moyamoya gel was normalized to the density of the corresponding spot in the control gel.
that familial moyamoya disease patients have much lower mitochondrial deoxyribonucleic acid (mtDNA) heterogeneity than that seen in the general Japanese population. Hong et al. documented HLA DRB1 and DQBI were elevated in familial moyamoya disease. Kang et al. suggested that the presence of a G/C heterozygous genotype at position -418 in the tissue inhibitor of metalloproteinases-2 (TIMP-2) promoter region could be a predisposing genetic factor for familial moyamoya disease. Researchers performing a CSF study in moyamoya patients have commented on correlations with b-FGF, ICAM-1, VCA-M-1, and E-selectin level. Histopathologic studies suggested the existence of mural thrombi is the most probable candidate for the cause of intimal lesions, and other studies have suggested a correlation with inflammatory stimuli. There have been no prior serologic studies of moyamoya disease. Our results show that complement C1 inhibitor protein was up-regulated (7.23 ± 0.10141 fold) in moyamoya patients. Complement C1 inhibitor protein reduces polymorphonuclear leukocyte accumulation and neuronal damage in focal ischemia and reperfusion. The early inhibition of the classical complement activation pathway by complement C1 inhibitor protein may help in protecting the penumbra zone in focal cerebral ischemia. In a model of cortical venous infarction, the infarct volume after complement inhibition (0.86 ± 0.23 mm³) was only 27.7% that of the group (3.09 ± 0.62 mm³). In ischemic mice receiving complement C1 inhibitor protein via intravenous injection, C1-INH significantly dampened the messenger ribonucleic acid (mRNA) expression of the adhesion molecules induced by the ischemic insult (P-selectin and ICAM-1). Also, it significantly decreased a pro-inflammatory cytokine [tumor necrosis factor (TNF)-alpha, interleukin (IL)-18], increased protective cytokine (IL-6, IL-10) gene expression, and markedly inhibited the activation and/or recruitment of microglia/macrophages. In moyamoya patients, the over-expression of complement C1 inhibitor protein may be associated with protection from ischemia and progressive obstruction of distal internal carotid artery (ICA).

Our study also found the Ig heavy chain V-III region (ART) was up-regulated (2.275 ± 0.44092). No other moyamoya studies have commented on this protein. We need to study this protein to find its correlation with moyamoya disease. Among down-regulated proteins in our result, apolipoprotein C-III was the lowest expressed protein (0.066 ± 0.05231). Apolipoprotein C-III induces both THP-1 cells and human peripheral monocytes to adhere to endothelial cells. In addition, ApoC-III is known to increase VCAM-1 and ICAM-1 protein expression in non-activated endothelial cells. Study of Masuda et al. provided evidence that, in moyamoya, smooth muscle cells proliferate in intracranial major arteries’ occlusive lesions. Colonization due to inflammatory stimuli may induce a proliferative response by smooth muscle and contribute to the formation of intracranial occlusive lesions in moyamoya disease. We assume that the down-regulation of apolipoprotein C-III is a biological protection, reducing the formation of intracranial occlusive lesions.

We could not verify the other down-regulated proteins (a coeval dimer of transthyretin, a retinol-binding protein, a proapolipoprotein, PRO 2675, PRO2044, apolipoprotein E precursor, the X-ray crystal structure of C3d, S100 calcium binding protein A14, ALB protein, and a hypothetical protein) as having any relation to moyamoya disease.

Caillon et al. described how one potential use of transthyretin, in serological tests for the non-invasive diagnosis of liver fibrosis, opens new opportunities for better follow-up of hepatitis C virus-infected patients. Hybelová et al. pointed out the substantial clinical value to be found in MS patients’ levels of CSF and serum transthyretin. Report of Chiang et al. demonstrated that the CSF transthyretin concentration of GBS patients was significantly higher than that of the multiple sclerosis, Alzheimer’s disease, and viral meningitis patients and the controls.

Regarding the retinol-binding protein, study of Kwon et al. suggested that RBP4 is a serologic marker for disease severity in patients with chronic liver disease and could also be useful as an early marker of chronic liver disease and the relative success of antiviral therapy. Nobili et al. showed an inverse relationship between RBP4 levels and degree of liver damage. RBP4 therefore might be a novel, noninvasive marker of the severity of pediatric nonalcoholic fatty liver disease. Kim et al. described how serum concentrations of proapolipoprotein A1 were higher in breast cancer patients. Park et al. reported that proteomic analysis of amniotic fluid can distinguish preeclampsia from chronic hypertension and identified the discriminatory proteins as proapolipoprotein A-I and SBB142.

PRO 2675, PRO 2044, apolipoprotein E precursor, the X-ray crystal structure of C3d, S100 calcium binding protein A14, ALB protein, and the hypothetical protein have no reported serological significance.

Although our experimental group is small, each patient was at different stage of the disease and had different clinical symptom. Therefore, the over-expressed proteins and down-regulated proteins are not limited to a specific stage of moyamoya disease. This suggests that these proteins correlate to the general pathophysiology of moyamoya disease.

The proteins that were not readily identifiable in this study
(spots 12, 29, 92, 383, 670, 1003, and 2354) may be novel proteins in the pathophysiology of moyamoya disease. We need to study further of these proteins.

**CONCLUSION**

We found 22 particular serum proteins in patients with moyamoya disease, as compared with normal controls. These proteins may provide clues regarding the pathophysiology of moyamoya disease.

**References**

1. Akita N, Nakase H, Kaido T, Kanemoto Y, Sakaki T : Protective effect of Cl esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. *Neurosurgery* 52 : 395-400; discussion 400-401, 2003
2. Caillot F, Hiron M, Goria O, Gueudin M, Francois A, Scotte M, et al. : Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. *Am J Pathol* 175 : 46-53, 2009
3. Chiang HL, Lyu RK, Tsiang MY, Chang KH, Chang HS, Hsu WC, et al. : Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barre syndrome and other neurological disorders. *Clin Chim Acta* 405 : 143-147, 2009
4. Fukui M, Kono S, Sueishi K, Ikezaki K : Moyamoya disease. *Neuropathology* 20 Suppl : S61-S64, 2000
5. Fukuyama Y, Otsawa M, Kanai N : Moyamoya disease (syndrome) and the Down syndrome. *Brain Dev* 14 : 254-256, 1992
6. Geppert A, Takeshima T, Horstick G, Kempski O : Cl-esterase inhibitor reduces infarct volume after cortical vein occlusion. *Brain Res* 838 : 210-213, 1999
7. Hong SH, Wang KC, Kim SK, Cho BK, Park MH : Association of HLA-DR and -DQ genes with familial moyamoya disease in Koreans. *J Korean Neurosurg Soc* 46 : 558-563, 2009
8. Hosoda Y, Ikeda E, Hirose S : Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). *Clin Neurol Neurosurg* 99 Suppl 2 : S203-S208, 1997
9. Hybelová M, Svatonová J, Sobek O, Adam P, Doležal D, Adam D : Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS) : comparison of particular subgroups of MS patients. *Folia Microbiol (Praha)* 54 : 173-176, 2009
10. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Atarimai T : Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. *Am J Hum Genet* 64 : 533-537, 1999
11. Ikeda H, Yoshimoto T : Specific genetic characteristics in patients with familial moyamoya disease. *J Stroke Cerebrovasc Dis* 14 : 244-250, 2005
12. Inoue TK, Ikazaki K, Sasazuki T, Matsumura T, Fukui M : Linkage analysis of moyamoya disease on chromosome 6. *J Child Neurol* 15 : 179-182, 2000
13. Kang HS, Kim SK, Cho BK, Kim YY, Hwang YS, Wang KC : Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. *Neurosurgery* 58 : 1074-1080; discussion 1074-1080, 2006
14. Kawakami A, Akikawa M, Akaia P, Lucekens FW, Libby P, Sacks FM : Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. *Circulation* 114 : 681-687, 2006
15. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. : The multiplex bead array protocol to identify serum biomarkers associated with breast cancer. *Breast Cancer Res* 11 : R22, 2009
16. Kwon JH, Park ST, Kim GD, You CR, Kim JG, Woo HY, et al. : [The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease.] *Korean J Hepatol* 15 : 59-69, 2009
17. Masuda J, Ogata J, Yutani C : Smooth muscle cell proliferation and localization of macrophages and T cell in the occlusive intracranial major arteries in moyamoya disease. *Stroke* 24 : 1960-1967, 1993
18. Nobili V, Alkhouri N, Alisi A, Ostino S, Lopez R, Manco M, et al. : Retinol-binding protein 4 : a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 7 : 575-579, 2009
19. Park JS, Oh KJ, Norwitz ER, Han JS, Choi HJ, Seong HS, et al. : Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. *Reprod Sci* 15 : 457-468, 2008
20. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al. : A novel susceptibility locus for moyamoya disease on chromosome 8q23. *J Hum Genet* 49 : 278-281, 2004
21. Scheler C, Lamer S, Pan Z, Li XF, Salnikow J, Junghäut P : Peptide mass fingerprint sequence coverage from differently stained proteins on two-dimensional electrophoresis patterns by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS). *Electrophoresis* 19 : 918-927, 1998
22. Soriano SG, Cowan DB, Proctor MR, Scott RM : Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. *Neurosurgery* 50 : 544-549, 2002
23. Storini C, Rossi E, Marrella V, Distaso M, Vehrhaus R, Vergani C, et al. : Cl-esterase inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. *Neurobiol Dis* 19 : 10-17, 2005
24. Suzuki J, Takaku A : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. *Arch Neurol* 20 : 288-299, 1969
25. Wakai K, Yamashita A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. : Epidemiological features of moyamoya disease in Japan : findings from a nationwide survey. *Clin Neurol Neurosurg* 99 Suppl 2 : S1-S5, 1997
26. Yamashita T, Houkin K, Tada M, Abe H : Familial occurrence of moyamoya disease. *Clin Neurol Neurosurg* 99 Suppl 2 : S162-S167, 1997
27. Yamashita T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kurotoda S, et al. : Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. *Stroke* 31 : 930-935, 2000
28. Yoshimoto T, Houkin K, Takahashi A, Abe H : Evaluation of cytokines in cerebrospinal fluid from patients with moyamoya disease. *Clin Neurol Neurosurg* 99 Suppl 2 : S218-S220, 1997